NovaBay Pharmaceuticals Files 8-K

TL;DR

NovaBay filed a standard 8-K, no major news.

AI Summary

NovaBay Pharmaceuticals, Inc. filed an 8-K on September 18, 2025, to report current information. The filing does not contain specific financial details or material events beyond the standard reporting requirements for a current report.

Why It Matters

This filing indicates NovaBay Pharmaceuticals, Inc. is fulfilling its regulatory reporting obligations by submitting a current report.

Risk Assessment

Risk Level: low — This is a routine filing with no new material information or significant financial disclosures.

Key Players & Entities

• NovaBay Pharmaceuticals, Inc. (company) — Registrant
• September 18, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-33678 (identifier) — Commission File Number
• 68-0454536 (identifier) — IRS Employer Identification No.
• 2000 Powell Street, Suite 1150, Emeryville, CA 94608 (address) — Principal executive offices
• (510) 899-8800 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share NBY NYSE American Indic
• $0.80 — f the one-time special cash dividend of $0.80 per share for the Company's common stoc

Filing Documents

• novabay_8k.htm (8-K) — 25KB
• novabay_ex99-1.htm (EX-99.1) — 13KB
• ex99-1_001.jpg (GRAPHIC) — 6KB
• 0001829126-25-007498.txt ( ) — 211KB
• nby-20250918.xsd (EX-101.SCH) — 3KB
• nby-20250918_lab.xml (EX-101.LAB) — 33KB
• nby-20250918_pre.xml (EX-101.PRE) — 22KB
• novabay_8k_htm.xml (XML) — 4KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 18, 2025, NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (the "Company") announced that, because the payment of the one-time special cash dividend of $0.80 per share for the Company's common stock, which is to be paid on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025, represents more than 25% of the price of the Company's common stock, NYSE American advised the Company that its common stock will trade with "due bills" representing an assignment of the right to receive the special dividend from the record date of September 15, 2025 through the close of trading on NYSE American on September 29, 2025, which is the payment date and the last day of trading before the September 30, 2025 ex-dividend date (this period of time representing the "Dividend Right Period"). Stockholders who sell their common stock during the Dividend Right Period will be selling their right to the special dividend, and such stockholders will not be entitled to receive the special dividend. Due bills obligate a seller of common stock to deliver the special dividend payable on such common stock to the buyer (i.e., a dividend right). Due bill obligations are customarily settled between the brokers representing the buyers and the sellers of shares. The Company has no obligation for either the amount of the due bill or the processing of the due bill. Buyers and sellers of the Company's common stock should consult their brokers before trading to be sure they understand the effect of NYSE American's due bill procedures.

01. Financial

Item 9.01. Financial (d) Exhibits. Exhibit No. Exhibit 99.1 Press release, dated September 18, 2025, from the Company 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: September 18, 2025 NovaBay Pharmaceuticals, Inc. By: /s/ David Lazar Name: David Lazar Title: Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR